Latest Advances in Lung Cancer Research

Japan approves Tagrisso with chemotherapy as a new first-line treatment for EGFR-mutated advanced lung cancer.

Lung cancer in never-smokers may respond poorly to immunotherapy due to genetic mutations, suggesting a need for tailored treatments.

Immunotherapy and chemotherapy before surgery show promise for stage 3 NSCLC patients, with 77% achieving two-year progression-free survival.

Dato-DXd shows promise in treating advanced “HER2-low” lung cancer, slowing progression and potentially extending survival.

Stepped palliative care for advanced lung cancer improves quality of life by integrating symptom management and emotional support earlier.

Osimertinib significantly extends progression-free survival in stage III EGFR-mutant lung cancer patients. The drug shows promise as a new standard treatment after chemo and radiation, with manageable side effects.

New treatments for lung cancer, including targeted therapies and immunotherapy, are extending lives and offering hope for patients.

Tagrisso significantly improves survival in patients with unresectable stage III EGFR-mutated lung cancer, offering new hope for a longer life.

Lorbrena, a new drug targeting a key protein in cancer cells, shows promise in extending survival for non-small cell lung cancer patients.

The Food and Drug Administration on Thursday approved Amgen’s therapy for patients with the most deadly form of lung cancer.

On May 16, 2024, the Food and Drug Administration granted accelerated approval to tarlatamab-dlle (Imdelltra) for extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.